Pfizer’s First-Launched Vyndamax Patent Case Is Down to Validity

Pfizer Inc.’s courtroom campaign to protect its blockbuster heart drug Vyndamax from cheaper versions got some help Friday, as one of four generic-drug makers in the consolidated case conceded its copy infringes three patents, leaving only their validity at issue.

Dexcel Pharma Technologies Ltd.’s proposed generic will infringe US Patent Nos. 7,214,695, 7,214,696, and 9,770,441 if the asserted patent claims aren’t proven invalid, according to a stipulation and proposed order of infringement that Magistrate Judge Christopher J. Burke approved in the US District Court for the District of Delaware.

Such concessions are a common tactic that allows an accused ...